What did Leerink Partners do on March 18, 2026 for BTSG?

Leerink Partners reiterated an **Outperform** on March 18, 2026 for BrightSpring Health Services. The note followed Investor Day and included no new price target.

Does the March 18 note include a BTSG price target?

No. The March 18, 2026 Leerink note maintained the Outperform rating but did not publish a new BTSG price target in the report we reviewed [StreetInsider](https://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Reiterates+Outperform+on+BrightSpring+Health+%28BTSG%29+after+Investor+Day/261820

How should investors interpret a maintained BTSG analyst rating?

A maintained rating shows ongoing analyst confidence without stronger conviction. It means the analyst sees potential but wants more evidence before raising the forecast or price target.

What is Meyka’s view and grade for BTSG?

Meyka AI rates BTSG with a grade of **B+**. This grade reflects benchmark and sector comparisons, growth, key metrics, and analyst consensus; it is not investment advice.

Analyst Ratings

Leerink Maintains Outperform on BTSG BrightSpring Health Services Mar 18 2026

ByDanny Kontos March 19, 2026

Leerink Partners maintained an Outperform on BrightSpring Health Services, Inc. Common Stock (BTSG) on March 18, 2026. The BTSG analyst rating was reiterated after the company’s Investor Day. Leerink flagged strategy progress but did not change its view. The market reacted with a -2.92% intraday move, equal to $-1.30. We review what the March 18 action means, the lack of a new price target, and how investors should read the note in context.